Alnylam announces first patient dosed in zenith global phase 3 cardiovascular outcomes trial of zilebesiran

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the first patient has been dosed in zenith (zilebesiran cardiovascular outcome study in hypertension), a global phase 3 cardiovascular outcomes trial (cvot) designed to evaluate the potential of zilebesiran, an investigational biannual subcutaneously administered rnai therapeutic, to reduce the risk of major adverse cardiovascular (cv) events in patients w.
ALNY Ratings Summary
ALNY Quant Ranking